Dataset Information

The Correlation between YAP and RhoA Expression in Prostate and Ovarian Tumor Stroma.

ABSTRACT:

Background and objective

Cancer associated fibroblasts (CAFs) are a mesenchymal cell type found in most solid tumors modulating cancer metastasis by building up and remodeling the extracellular matrix (ECM) structure. We aimed to evaluate the correlation between RhoA and YAP expression in the stroma cells obtained from prostate and ovarian cancer tissues.

Methods

We analyzed two microarray datasets obtained from NCBI Gene Expression Omnibus(GEO). The sample type of two datasets was RNA, which is displaying the transcriptome profiling. The tumor stroma of patients with invasive prostate cancer and high-grade serous ovarian cancer were obtained from datasets Independent t-test was used to analyze the differentially expressed YAP between normal stroma and cancer stroma. In addition, Pearson's correlation was run to analyze the correlation between YAP and RhoA expressions.

Results

In comparison with normal stroma tissues, YAP1 was overexpressed in prostate and ovarian cancer stroma tissues (prostate cancer stroma, p <0.05; ovarian cancer stroma, p < 0.001). Furthermore, a positive correlation was detected between YAP and RhoA expressions in stroma of both tumor types. This correlation was positively strong in prostate cancer stroma (R=0.607) and positively weak in ovarian cancer stroma (R=0.248).

Conclusion

We found that YAP was overexpressed in prostate and ovarian cancer stroma. Furthermore, the correlation between RhoA and YAP expression suggested that RhoA-YAP signals could physiologically be involved in tumor stroma. Thus, targeting RhoA-YAP may be an intriguing avenue for cancer therapeutics in neoplastic epithelial cells as well as tumor stroma.

SUBMITTER: Lee MJ

PROVIDER: S-EPMC9258680 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BackgroundDespite the promise of dual BRAF/MEK inhibition as a therapy for BRAF-mutant (BRAF-mut) melanoma, heterogeneous responses have been observed in patients, thus predictors of benefit from therapy are needed. We have previously identified semaphorin 6A (SEMA6A) as a BRAF-mut-associated protein involved in actin cytoskeleton remodeling. The purpose of the present study is to dissect the role of SEMA6A in the biology of BRAF-mut melanoma, and to explore its predictive potential towards dual BRAF/MEK inhibition.MethodsSEMA6A expression was assessed by immunohistochemistry in melanoma cohort RECI1 (N = 112) and its prognostic potential was investigated in BRAF-mut melanoma patients from DFCI and TCGA datasets (N = 258). The molecular mechanisms regulated by SEMA6A to sustain tumor aggressiveness and targeted therapy resistance were investigated in vitro by using BRAF-mut and BRAF-wt melanoma cell lines, an inducible SEMA6A silencing cell model and a microenvironment-mimicking fibroblasts-coculturing model. Finally, SEMA6A prediction of benefit from dual BRAF/MEK inhibition was investigated in melanoma cohort RECI2 (N = 14).ResultsOur results indicate higher protein expression of SEMA6A in BRAF-mut compared with BRAF-wt melanoma patients and show that SEMA6A is a prognostic indicator in BRAF-mut melanoma from TCGA and DFCI patients cohorts. In BRAF-mut melanoma cells, SEMA6A coordinates actin cytoskeleton remodeling by the RhoA-dependent activation of YAP and dual BRAF/MEK inhibition by dabrafenib+trametinib induces SEMA6A/RhoA/YAP axis. In microenvironment-mimicking co-culture condition, fibroblasts confer to melanoma cells a proliferative stimulus and protect them from targeted therapies, whereas SEMA6A depletion rescues the efficacy of dual BRAF/MEK inhibition. Finally, in BRAF-mut melanoma patients treated with dabrafenib+trametinib, high SEMA6A predicts shorter recurrence-free interval.ConclusionsOverall, our results indicate that SEMA6A contributes to microenvironment-coordinated evasion of melanoma cells from dual BRAF/MEK inhibition and it might be a good candidate predictor of short-term benefit from dual BRAF/MEK inhibition.